Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis

Area of Science:

• Rheumatology
• Cardiology
• Biochemistry

Background:

• Cardiovascular disease (CVD) is a primary cause of death in rheumatoid arthritis (RA).
• Current RA treatments improve joint health but not cardiovascular outcomes, leaving a significant unmet need.
• The mechanisms behind accelerated atherosclerosis in RA and early CVD markers remain unclear.

Purpose of the Study:

• To review the causes of elevated methylarginine levels in RA.
• To explore the role of methylarginines in RA-associated atherosclerosis.
• To discuss methylarginines as potential biomarkers and therapeutic targets for CVD risk in RA.

Main Methods:

• Literature review focusing on methylarginines, endothelial dysfunction, and atherosclerosis in RA.
• Analysis of studies investigating methylarginine metabolism and CVD risk factors in RA patients.
• Examination of current pharmacological treatments and their impact on cardiovascular risk in RA.

Main Results:

• Asymmetric dimethylarginine (ADMA) is implicated in endothelial dysfunction and subclinical atherosclerosis in RA.
• Elevated methylarginine levels are linked to increased cardiovascular risk in RA patients.
• The methylarginine metabolic pathway presents potential therapeutic targets for reducing CVD risk.

Conclusions:

• Increased methylarginine levels contribute to accelerated atherosclerosis in RA.
• Methylarginines show promise as biomarkers for early CVD detection in RA.
• Targeting methylarginine metabolism may offer novel therapeutic strategies for managing cardiovascular risk in RA.